Manolis Kellis News Today

Following MIT President Sally Kornbluth’s second call for proposals, 16 teams of MIT scholars have been selected to develop research papers analyzing the impact of generative AI on a broad range of topics and disciplines.

On the surface, the movement disorder amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and the cognitive disorder frontotemporal lobar degeneration (FTLD), which underlies frontotemporal dementia, manifest in very different ways. In addition, they are known to primarily affect very different regions of the brain.

On his podcast, Fridman has spoken to the likes of Elon Musk, Mark Zuckerberg, Jeff Bezos, Benjamin Netanyahu, Robert F. Kennedy Jr., Ye, and Joe Rogan.

MIT student Gitanjali Rao was honored by First Lady Jill Biden at the first Girls Leading Change celebration held at the White House. Rao, a first-year undergraduate, is an accomplished inventor and author.

Presenters at MIT’s Aging Brain Initiative Symposium delivered a rich and diverse sampling of the university’s research to address neurodegenerative diseases such as Alzheimer’s and ALS.

A new genetic model takes into account data from people across diverse ancestries. The polygenic model, developed at MIT, dramatically increased accuracy of predictions for many traits, especially for people from previously underrepresented populations.

Alzheimer's disease affects more than 6 million people in the United States, and there are very few FDA-approved treatments that can slow the progression of the disease.

Using more than 2 million cells from over 400 postmortem brain samples, MIT researchers performed the largest-scale analysis of the genomic, epigenomic, and transcriptomic changes that occur in every cell type in the brains of Alzheimer’s patients.

People with an abundance of specific neurons are more likely to escape cognitive decline despite having signs of Alzheimer’s in their brains. People with an abundance of specific neurons are more likely to escape cognitive decline despite having signs of Alzheimer’s in their brains.

Innovating at the intersection of chemistry, biology, and engineering, Professor Brad Pentelute and the MIT Pentelute Laboratory are revolutionizing